InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,881.93
(
0.14%
)
Post# of 648882
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 219
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: None

Tuesday, 09/19/2017 8:02:28 AM

Tuesday, September 19, 2017 8:02:28 AM

Post# of 648882
The FDA approves GlaxoSmithKline's (NYSE:GSK) Trelegy Ellipta [fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)], a once-daily, single inhaler triplet therapy for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Market launch will commence shortly.

Glaxo developed the product with collaboration partner Innoviva (NASDAQ:INVA). Approval in Europe should happen in Q4.

Pray for A Pain Free Day!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up